430P - Demographic data and treatment outcome in retinoblastoma: retrospective review from tertiary centre in India

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Aetiology, Epidemiology, Screening and Prevention
Central Nervous System Malignancies
Basic Scientific Principles
Presenter Faiz Akram Ansari
Authors F.A. Ansari1, P. Shukla2, V. Roshan3, B. Mohanti3
  • 1Radiation Oncology, aiims, delhi/IN
  • 2Radiation Oncology, All India Institute of Medical Sciences (AIIMS) Institute Rotary Cancer Hospital, 110029 - New Delhi/IN
  • 3Radiotherapy, aiims, delhi/IN



To characterize the patient population and analyse treatment outcome in patients with retinoblastoma.

Method and material

A retrospective study of 180 patients with retinoblastoma affecting a total of 297 eyes. Demographic data, tumor features and outcome were assessed.


The mean age of diagnosis was 32 months (range 2-204 months) for unilateral eyes and 26 months ( range 2-132months) for bilateral eyes. The male to female ratio was 1.4:1. The most common symptoms was leukokoria (74%), followed by proptosis of eye (11.5%), strabismus (8%) and poor vision (6.5%). Out of 297 eyes 39 were Group I-II, 17 were Group III, 198 were group IV-V and 43 had missing information. The mean basal diameter was 14mm (range 2–37mm). The mean interval between initial diagnosis and treatment was 7months ( range 1-36 months). Familial history was seen in eight patients (4.4%). Out of 180 patients 64 patients received radiation. 144 patients underwent enucleation. No children underwent bilateral enucleation. All patients were treated with 6–12 cycles of chemotherapy vincristine, etoposide and carboplatin. Chemotherapy offer satisfactory local control for Group I-III, with treatment failure necessitating additional radiation and or enucleation in only 14% of patients. The radiation doses were either 39Gy in 13 fraction, three fraction per week or 40Gy in 20 fraction, five fraction per week. The mean duration of follow up was 28 months (0-64months). The overall local control or freedom from relapse was 55%. Local control in patients receiving radiation after enucleation was 84%. Distant metastases were seen in 13 patients (preauricular node (5), vertebrae (3), humerus (1), suprasellar (1), scalp (1), CSF(1), and meningeal dissemination (1)). No case of second malignant neoplasm has been reported.


Lack of awareness leads to delay in diagnosis and treatment. Multimodality treatment is required for management of retinoblastoma. Chemoreduction offer satisfactory control retinoblastoma in group I-III, with preservation of vision. There is significant improvement in local control with radiation therapy in locally advance cases.


All authors have declared no conflicts of interest.